.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB13_PeginterferonBeta1a.PeginterferonBeta1a

Information

Peginterferon beta-1a is a pegylated form of interferon beta-1a approved for the treatment of relapsing forms of multiple sclerosis (MS). The PEGylation increases the half-life, allowing for less frequent dosing compared to conventional interferon beta-1a preparations. It is currently approved and in clinical use.

Pharmacokinetics

Pharmacokinetic parameters are reported for adult patients with relapsing-remitting MS. Most data are from healthy subjects and MS patients administered a subcutaneous dose of 125 micrograms every 2 weeks.

References

1. Zhao, Y, et al., & Butts, CL (2022). Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study. Med (New York, N.Y.) 3(9) 612–621.e3. DOI:10.1016/j.medj.2022.06.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35853458

2. Hoy, SM (2015). Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS drugs 29(2) 171–179. DOI:10.1007/s40263-015-0227-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25666445

3. Hu, X, et al., & Werneburg, B (2016). COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. British journal of clinical pharmacology 82(2) 380–388. DOI:10.1111/bcp.12968 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27060836

Revisions

• 06/2025 initial generated model